a phase 2 randomised study of ramucirumab (imc-1121b) with or without dacarbazine in patients with metastatic melanoma：治疗的2期随机研究（imc-1121b）伴或不伴转移性黑色素瘤患者组.pdf

European Journal of Cancer (2014) 50, 2099– 2107 A v a i l a b l e a t w w w . s c i e n c e d i r e c t. c o m ScienceDirect journal homepag e: A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma a,⇑ b c d Richard D. Carvajal , Michael K. Wong , John A. Thompson , Michael S. Gordon , e f a g Karl D. Lewis , Anna C. Pavlick , Jedd D. Wolchok , Patrick B. Rojas , Jonathan D. Schwartz g, Agop Y. Bedikian h a Memorial Sloan-Kettering Cancer Center, New York, NY, USA b USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA c Seattle Cancer Care Alliance, Seattle, WA, USA d Pinnacle Oncology Hematology, Scottsdale, AZ, USA e University of Colorado Denver, Aurora, CO, USA f New York University, New York, NY, USA g ImClone Systems LLC, a wholly-owned subsidiary of Eli Lilly and Company, Bridgewater, NJ, USA h MD Anderson Cancer Center, Houston, TX, USA Received 8 November 2013; received in revised form 27 January 2014; accepted 26 March 2014 Available online 12 June 2014 KEYWORDS Abstract Background: To evaluate the efficacy and safety of ramucirumab (IMC-1121B; Metastatic melanoma LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth Phase II factor receptor-2, alone and in combination with dacarbazine in chemoth